Replies to post #6077 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

Correction—#6075 should say:

Including calendar 1Q26 (for which ENTA’s gross royalty from ABBV will be ~$17M), ENTA’s cumulative payments to OMERS will amount to about $108M in only 2.5 years. That leaves $176M to reach the $284M ceiling.

In the original post, I forgot to divide by 2 when calculating ENTA’s calendar-1Q26 gross royalty.

This arithmetic error does not materially change the discussion of ENTA’s cash-runway guidance in #msg-177552842.